Lactose engineering for better performance in dry powder inhalers
Related Experiment Video
Updated: May 5, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Yahya Rahimpour1, Hamed Hamishehkar
1Biotechnology Research Center and Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Abstract:
Dry powder inhaler (DPI) is generally formulated as a powder mixture of coarse carrier particles and micronized drug with aerodynamic diameters of 1-5 μm. Carrier particles are used to improve drug particle flowability, thus improving dosing accuracy, minimizing the dose variability compared with drug alone and making them easier to handle during manufacturing operations. Lactose is the most common and frequently used carrier in DPIs formulations and nowadays various inhalation grades of lactose with different physico-chemical properties are available on the market. Therefore, the purpose of this manuscript is to review evolution of lactose as a carrier in inhalable formulations, their production and the impact of its physico-chemical properties on drug dispersion. This review offers a perspective on the current reported studies to modify lactose for better performance in DPIs.
Related Concept Videos
Inhaled Medications
Production of Pharmaceuticals
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Factors Influencing Drug Absorption: Pharmaceutical Parameters
Bioavailability Enhancement: Drug Permeability Enhancement
Modified-Release Drug Delivery Systems: Rate-Programmed I

